CORAT’s CEO Dr. Andreas Herrmann and CSO Dr. André Frenzel comment in international television on the start of clinical studies with CORAT Therapeutics SARS-CoV-2 neutralising antibody COR-101 against COVID-19 in hospitalized patients.

The article can be viewed at the following link:

COVID-19 Special: The challenge of developing a cure

Source: Deutsche Welle Berlin